Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to $2.7 million.

  • Gossamer Bio's Share-based Compensation fell 44.94% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year decrease of 41.80%. This contributed to the annual value of $20.6 million for FY2024, which is 27.70% down from last year.
  • Latest data reveals that Gossamer Bio reported Share-based Compensation of $2.7 million as of Q3 2025, which was up 3.09% from $2.6 million recorded in Q2 2025.
  • Gossamer Bio's Share-based Compensation's 5-year high stood at $11.4 million during Q4 2022, with a 5-year trough of $2.4 million in Q1 2025.
  • Over the past 3 years, Gossamer Bio's median Share-based Compensation value was $5.0 million (recorded in 2024), while the average stood at $5.2 million.
  • Data for Gossamer Bio's Share-based Compensation shows a maximum YoY slumped of 58.61% (in 2025) over the last 5 years.
  • Gossamer Bio's Share-based Compensation (Quarterly) stood at $11.4 million in 2022, then slumped by 47.31% to $6.0 million in 2023, then decreased by 17.69% to $5.0 million in 2024, then plummeted by 44.94% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.6 million for Q2 2025, and $2.4 million during Q1 2025.